Difference between revisions of "Axitinib (Inlyta)"
m (categories) |
m (Text replace - "Category:Tyrosine kinase inhibitors" to "Category:Kinase inhibitors") |
||
Line 22: | Line 22: | ||
[[Category:Drug index]] | [[Category:Drug index]] | ||
[[Category:Chemotherapy]] | [[Category:Chemotherapy]] | ||
− | [[Category: | + | [[Category:Kinase inhibitors]] |
[[Category:VEGF inhibitors]] | [[Category:VEGF inhibitors]] | ||
[[Category:PDGFR inhibitors]] | [[Category:PDGFR inhibitors]] |
Revision as of 05:56, 30 May 2013
FDA approved 1/27/2012 Also known as AG013736.
General information
Class/mechanism: Tyrosine kinase inhibitor of multiple receptor tyrosine kinases, including vascular endothelial growth factor receptors VEGFR-1, VEGFR-2, and VEGFR-3, which interferes with tumor angiogenesis, growth, and cancer progression.[1][2][3]
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
Patient drug information
- Axitinib (Inlyta) patient drug information (Pfizer)[4]
- Axitinib (Inlyta) patient drug information (Chemocare)[5]
- Axitinib (Inlyta) patient drug information (UpToDate)[6]
References
- ↑ 1.0 1.1 Axitinib (Inlyta) package insert
- ↑ Axitinib (Inlyta) package insert (locally hosted backup)
- ↑ Matthew Stenger. What You Need to Know About Axitinib, New Agent for Treating Advanced Renal Cell Carcinoma. ASCO Post, March 15, 2012, Volume 3, Issue 5.
- ↑ Axitinib (Inlyta) patient drug information (Pfizer)
- ↑ Axitinib (Inlyta) patient drug information (Chemocare)
- ↑ Axitinib (Inlyta) patient drug information (UpToDate)